José María López-Picazo González-rekin lankidetzan egindako argitalpenak (8)

2022

  1. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

2021

  1. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2015

  1. Functional expression of CD137 (4-1BB) on T helper follicular cells

    OncoImmunology, Vol. 4, Núm. 12

2014

  1. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

2009

  1. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

2007

  1. Nuevos tratamientos para el carcinoma renal

    Anales del sistema sanitario de Navarra, Vol. 30, Núm. 3, pp. 393-403